Open AccessPredictive markers of the efficacy of colon adenocarcinoma treatment by 5-fluoropyrimidines determined by means of immunohistochemistry method
Author(s) -
Г. А. Раскин,
Р. В. Орлова,
Anna E. Protasova,
С. А. Кошкин,
Ruslan I. Glushakov
Publication year - 2014
Publication title -
obzory po kliničeskoj farmakologii i lekarstvennoj terapii
Language(s) - English
Resource type - Journals
eISSN - 2542-1875
pISSN - 1683-4100
DOI - 10.17816/rcf12450-53
Subject(s) - thymidylate synthase , dihydropyrimidine dehydrogenase , thymidine phosphorylase , folfox , colorectal cancer , folfiri , medicine , immunohistochemistry , adenocarcinoma , oncology , fluorouracil , gastroenterology , chemotherapy , cancer research , cancer , oxaliplatin
5-fluorouracil (5-FU) has remained the treatment of choice in the adjuvant and palliative setting of colon cancer (CC).The purpose of this study was to evaluate the expression of the thymidine phosphorylase (TP), thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPYD)in CC patients treated with 5-fluorouracil (5-FU) to determine their predictive and prognostic significance. Immunohistochemistry (IHC) analysis of the expression of proteins was performed on tumour tissue of 104 patients with stage IV colon cancer. All patient was treated withfluoropyrimidine/antifolate-based therapy (FOLFOX, De Gramont, FOLFIRI). Usedmultivariate logistic regression analyses we found the level of expression of proteins thymidine phosphorylase (TP), thymidylate synthase (TS) as predictors efficiency 5 - fluoropyrimidine with adenocarcinoma of the colon. The value of expression of TP and TS has a statistically significant effect (p = 0,006 and p = 0.0036) on time to disease progression, respectively.Our data demonstrated the efficacy of the 5-fluoropyrimidine chemotherapy colon adenocarcinoma may be utilized evaluation of expression of TS and TP.